Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition

Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agonist drug developers that includes Takeda Pharmaceutical, Alkermes, and Eisai. The post Eli Lilly’s Neuro Prospects Expand to…

Read More

Jesse Shoplock, Inbox Health

Jesse Shoplock is SVP of Business Development at Inbox Health. They are trying to help one of the messiest parts of American health care, figuring out both how much patients owe at the point of care and how to actually help the providers get paid. As of now 70% of patients don’t know what they…

Read More

Readers Speak Out on Work Requirements, Federal Data Grab, Opioid Payback Cash

Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. Work Requirements Unfairly Burden Medicaid Applicants Great story (“A Deloitte-Run System Denied Medicaid Benefits for Michigan’s Disabled. Now Trump’s Law Piles On,” July 21). However, a key point was missed. The…

Read More

Why Epic’s Judy Faulkner Rejects the MBA Mindset

At Forbes Healthcare Summit, Epic CEO Judy Faulkner explained why the company’s long-protected independence and unconventional management approach have been central to its dominance as an EHR vendor. Now, she says the company’s future will depends on how it uses its massive data stores to support AI-powered clinical decisions. The post Why Epic’s Judy Faulkner…

Read More